References
- Tallman M S, Nabhan C, Feusner J H, Rowe J M. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 99: 759–767
- Evans G D, Grimwade D J. Extramedullary disease in acute promyelocytic leukemia. Leuk Lymphoma 1999; 33: 219–229
- Paydas S, Yavuz S, Disel U, Sahin B, Canbolat T, Tuncer I. Vasculitis associated with all trans retinoic acid (ATRA) in a case with acute promyelocytic leukemia. Leuk Lymphoma 2003; 44: 547–548
- Giralt S, O'brien S, Weeks E, Luna M, Kantarjian H. Leukemia cutis in acute promyelocytic leukemia: report of three cases after treatment with all-trans retinoic acid. Leuk Lymphoma 1994; 14: 453–456
- Liso V, Specchia G, Pogliani E M, Palumbo G, Mininni D, Rossi V, et al. Extramedullary involvement in patients with acute promyelocytic leukemia. A report of seven cases. Cancer 1998; 83: 1522–1528
- Zhang T D, Chen G Q, Wang Z G, Wang Z Y, Chen S J, Chen Z. Arsenic trioxide, a therapeutic agent for APL. Oncogene 2001; 20: 7146–7153
- Leoni F, Gianfaldoni G, Annunziata M, Fanci R, Ciolli S, Nozzoli C, et al. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation. Haematologica 2002; 87: 485–489
- Cai X, Shen Y L, Zhu Q, Jia P M, Zhou L, Huang Y, et al. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 2000; 14: 262–270
- Zhu Q, Zhang J W, Zhu H Q, Shen Y L, Flexor M, Jia P M, et al. Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood 2002; 99: 1014–1022
- Carmosino I, Latagliata R, Avvisati G, Breccia M, Finolezzi E, Lo Coco F, et al. Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia. Haematologica 2004; 89: 615–617